Sentien Biotechnologies, Inc. awarded NIH Phase I SBIR Award for Liver Program

In News

Sentien was awarded a NIH Phase I SBIR grant to expand the companies’ platform cell therapy technology into a new therapeutic indication – acute liver injury.